Leontios Pappas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leontios Pappas has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Ryan B. Corcoran
Division of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA
147 shared publications - Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
146 shared publications - David T. Ting
Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts
143 shared publications - Bryanna L. Norden
Massachusetts General Hospital Cancer Center Department of Medicine Harvard Medical School Boston MA USA
133 shared publications - Samuel J. Klempner
Division of Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
131 shared publications - Andrew T. Chan
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
130 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
A Phase II Study of Nivolumab and Ipilimumab with Radiotherapy in Patients with Metastatic, Microsatellite-Stable Colorectal Cancer
Purpose: Immune checkpoint inhibitors (ICI) have significantly altered the natural history of microsatellite instability (MSI)–high metastatic colorectal cancer (mCRC). For microsatellite-stable (MSS) refractory mCRC, ICIs recently demonstrated efficacy signals in patients without liver metastases. This study evaluated combined radiotherapy (RT) and ICI therapy in MSS mCRC. Patients and Methods: This multi-institution, open-label, single-arm phase II study enrolled patients with MSS mCRC previously treated with oxaliplatin, 5-fluorouracil, and irinotecan. Patients received combined RT and nivolumab/ipilimumab. The primary endpoint was the objective response rate (ORR) for unirradiated lesions. Secondary endpoints included the disease control rate (DCR) for unirradiated lesions, DCR and ORR of irradiated lesions, treatment-related adverse event (AE) rates, progression-free survival (PFS), and overall survival (OS). Results: Among 30 patients treated, the confirmed ORR was 10%. The DCR was 33.3% and the ORR was 10% in unirradiated lesions, whereas in irradiated lesions the ORR was 13.3% and the DCR was 83.3%. In eight patients without active liver metastases, the ORR was 25% [95% confidence interval (CI), 3.2%–65.1%], whereas in 22 patients with liver metastases the ORR was 4.6% (95% CI, 0.1%–22.8%). The median PFS was 2.4 months at a median follow-up of 19.8 months. The median OS of the cohort was 12.8 months (95% CI, 6.8–17.9 months). Treatment was tolerable, and only 10% of patients experienced grade 4 toxicity, which in all cases was lymphopenia. Conclusions: The combination of immunomodulating, nonablative doses of RT with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases. Trial Registration: This trial is registered under the name “Nivolumab + Ipilimumab + RT in MSS mCRC” (ClinicalTrials.gov Identifier: NCT04575922).
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessA Phase II Study of Nivolumab and Ipilimumab with Radiotherapy in Patients with Metastatic, Microsatellite-Stable Colorectal Cancer
Purpose: Immune checkpoint inhibitors (ICI) have significantly altered the natural history of microsatellite instability (MSI)–high metastatic colorectal cancer (mCRC). For microsatellite-stable (MSS) refractory mCRC, ICIs recently demonstrated efficacy signals in patients without liver metastases. This study evaluated combined radiotherapy (RT) and ICI therapy in MSS mCRC. Patients and Methods: This multi-institution, open-label, single-arm phase II study enrolled patients with MSS mCRC previously treated with oxaliplatin, 5-fluorouracil, and irinotecan. Patients received combined RT and nivolumab/ipilimumab. The primary endpoint was the objective response rate (ORR) for unirradiated lesions. Secondary endpoints included the disease control rate (DCR) for unirradiated lesions, DCR and ORR of irradiated lesions, treatment-related adverse event (AE) rates, progression-free survival (PFS), and overall survival (OS). Results: Among 30 patients treated, the confirmed ORR was 10%. The DCR was 33.3% and the ORR was 10% in unirradiated lesions, whereas in irradiated lesions the ORR was 13.3% and the DCR was 83.3%. In eight patients without active liver metastases, the ORR was 25% [95% confidence interval (CI), 3.2%–65.1%], whereas in 22 patients with liver metastases the ORR was 4.6% (95% CI, 0.1%–22.8%). The median PFS was 2.4 months at a median follow-up of 19.8 months. The median OS of the cohort was 12.8 months (95% CI, 6.8–17.9 months). Treatment was tolerable, and only 10% of patients experienced grade 4 toxicity, which in all cases was lymphopenia. Conclusions: The combination of immunomodulating, nonablative doses of RT with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases. Trial Registration: This trial is registered under the name “Nivolumab + Ipilimumab + RT in MSS mCRC” (ClinicalTrials.gov Identifier: NCT04575922).
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 137
Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas
Background: Comprehensive genomic profiling (CGP) is critical for optimal clinical care for gastrointestinal (GI) carcinomas. Outside of biliary tract cancers (BTCs), actionable fusions are uncommon and the utility of routine RNA-based fusion testing in GI cancers is not well established. We therefore evaluated routinely conducted RNA-based fusion testing in GI cancers at a single center. Methods: Patients with GI carcinomas who underwent RNA-based tissue fusion testing at Massachusetts General Brigham Cancer Institute were included. Tumors with fusions were characterized for molecular and histopathologic associations. RSPO2/3 fusions in lower GI cancers were further characterized for survival and benefit from targeted therapy. Results: A total of 2,300 patients with GI carcinomas were included; 139 (6.0%) had a detected fusion. BTCs had the highest fusion incidence (13.7%), mostly FGFR2. Fusions were detected in 3.5–7.7% of colorectal cancer (CRC), pancreatic, esophagogastric adenocarcinoma (EGA), and small bowel carcinomas. Fusions of BRAF, FGFR1–3, NTRK1/3, RSPO2/3, and NRG1 were rare (excepting FGFR2 in BTCs) but observed in 3 or more cancer types. RSPO2/3 fusions were the second most frequent overall (1.4%) and most frequent in CRC (2.6%) and small bowel cancers (5.8%). RSPO2/3 fusions were associated with poorly differentiated and mucinous histology, preserved mismatch repair, wild-type (WT) APC, and either KRAS or BRAF V600E mutations, however were not associated with differential survival in CRC patients receiving BRAF targeted therapy. Fifteen of 20 (75%) pancreatic tumors with fusions were KRAS WT; in KRAS-mutated pancreatic cancer, most fusions were of unclear significance. Receipt of fusion targeted therapy was associated with longer survival in fusion positive pancreatic cancers and FGFR2-fusion positive BTCs. 20 fusions detected in EGA were heterogenous, including FGFR, CLDN18, and RSPO2. Conclusions: RNA-based testing identifies potentially actionable fusions in a clinically significant fraction of GI carcinomas. Patients who receive fusion targeted therapy during their clinical course demonstrate longer survival, supporting CGP including fusion testing for all patients. Lower GI cancers harboring RSPO2/3 fusions have a distinct molecular and pathologic phenotype, but demonstrate few clinical differences. Several detected fusions had novel gene partners, highlighting the utility of partner-agnostic fusion testing.
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 137
Open AccessHistopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas
Background: Comprehensive genomic profiling (CGP) is critical for optimal clinical care for gastrointestinal (GI) carcinomas. Outside of biliary tract cancers (BTCs), actionable fusions are uncommon and the utility of routine RNA-based fusion testing in GI cancers is not well established. We therefore evaluated routinely conducted RNA-based fusion testing in GI cancers at a single center. Methods: Patients with GI carcinomas who underwent RNA-based tissue fusion testing at Massachusetts General Brigham Cancer Institute were included. Tumors with fusions were characterized for molecular and histopathologic associations. RSPO2/3 fusions in lower GI cancers were further characterized for survival and benefit from targeted therapy. Results: A total of 2,300 patients with GI carcinomas were included; 139 (6.0%) had a detected fusion. BTCs had the highest fusion incidence (13.7%), mostly FGFR2. Fusions were detected in 3.5–7.7% of colorectal cancer (CRC), pancreatic, esophagogastric adenocarcinoma (EGA), and small bowel carcinomas. Fusions of BRAF, FGFR1–3, NTRK1/3, RSPO2/3, and NRG1 were rare (excepting FGFR2 in BTCs) but observed in 3 or more cancer types. RSPO2/3 fusions were the second most frequent overall (1.4%) and most frequent in CRC (2.6%) and small bowel cancers (5.8%). RSPO2/3 fusions were associated with poorly differentiated and mucinous histology, preserved mismatch repair, wild-type (WT) APC, and either KRAS or BRAF V600E mutations, however were not associated with differential survival in CRC patients receiving BRAF targeted therapy. Fifteen of 20 (75%) pancreatic tumors with fusions were KRAS WT; in KRAS-mutated pancreatic cancer, most fusions were of unclear significance. Receipt of fusion targeted therapy was associated with longer survival in fusion positive pancreatic cancers and FGFR2-fusion positive BTCs. 20 fusions detected in EGA were heterogenous, including FGFR, CLDN18, and RSPO2. Conclusions: RNA-based testing identifies potentially actionable fusions in a clinically significant fraction of GI carcinomas. Patients who receive fusion targeted therapy during their clinical course demonstrate longer survival, supporting CGP including fusion testing for all patients. Lower GI cancers harboring RSPO2/3 fusions have a distinct molecular and pathologic phenotype, but demonstrate few clinical differences. Several detected fusions had novel gene partners, highlighting the utility of partner-agnostic fusion testing.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan–Meier curves for survival outcomes in patients with MSS/pMMR mCRC receiving ICI-based therapies, stratified by liver metastasis status at the time of ICI initiation. A, PFS: Patients without liver metastases had significantly higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median PFS was 2.1 months (95% CI, 1.59–2.62) in those with liver metastases and 2.5 months (95% CI, 2.22–2.71) in those without liver metastases (HR, 1.68; 95% CI, 1.13–2.5; P = 0.009). B, OS: Median OS was 11.53 months (95% CI, 3.01–20.06) in those without liver metastases and 6.17 months (95% CI, 2.87–9.46) in those with liver metastases (HR, 2.03; 95% CI, 1.35–3.06; P < 0.001).
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan–Meier curves for survival outcomes in patients with MSS/pMMR mCRC receiving ICI-based therapies, stratified by liver metastasis status at the time of ICI initiation. A, PFS: Patients without liver metastases had significantly higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median PFS was 2.1 months (95% CI, 1.59–2.62) in those with liver metastases and 2.5 months (95% CI, 2.22–2.71) in those without liver metastases (HR, 1.68; 95% CI, 1.13–2.5; P = 0.009). B, OS: Median OS was 11.53 months (95% CI, 3.01–20.06) in those without liver metastases and 6.17 months (95% CI, 2.87–9.46) in those with liver metastases (HR, 2.03; 95% CI, 1.35–3.06; P < 0.001).
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan-Meier curves for survival outcomes in MSS/pMMR mCRC patients receiving ICI-based therapies, stratified by liver metastases status at baseline
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan-Meier curves for survival outcomes in MSS/pMMR mCRC patients receiving ICI-based therapies, stratified by liver metastases status at baseline
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Sites of progressive disease during immune checkpoint inhibitor-based therapy
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Sites of progressive disease during immune checkpoint inhibitor-based therapy
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for PFS.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for PFS.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.Significance:The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.Significance:The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.